Figure 5
From: Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia
Effect of tivantinib, ABT-199 and their combination on primary AML patient blasts. (a) Dotplot of relative primary AML BMNCs colony formation following treatment with tivantinib, ABT-199 or their combination for 14 or 19 days. Counts were averaged and normalized to DMSO. Patient mutational status for commonly altered genes is displayed. (b) Absolute primary AML blast colony count for patients 3 and 4 following treatment for 19 and 14 days, respectively. Synergy values (deviation from Bliss) are annotated. Combo = 1 μM tivantinib + 0.5 μM ABT-199.
